Internal Medicine Unit, Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Piazza L. Miraglia, 80138 Naples, Italy.
Department of Internal Medicine, Betania Evangelical Hospital, Via Argine, 80147 Naples, Italy.
Rev Cardiovasc Med. 2022 Mar 17;23(3):106. doi: 10.31083/j.rcm2303106.
Type 2 Diabetes Mellitus (T2DM) is associated with an elevated incidence of cardiovascular and renal diseases, responsible for mortality rates significantly higher than in the general population. The management of both cardiovascular risk and progression of kidney disease thus seem crucial in the treatment of the diabetic patient. The availability of new classes of drugs which positively affect both cardiovascular and renal risk, regardless of the glycemic control, represents a revolution in the treatment of T2DM and shifts the attention from the intensive glycemic control to a holistic management of the diabetic patient. Among these, sodium-glucose cotransporter-2 inhibitors (SGLT2i) have been associated with a remarkable reduction of cardiovascular and renal mortality, lower hospitalization rates for heart failure and lower progression of renal damage and albuminuria. Thus, their use in selected subpopulations seems mandatory. Aim of this review was the assessment of the current evidence on SGLT2i and their related impact on the cardiovascular and renal profiles.
2 型糖尿病（T2DM）与心血管和肾脏疾病的发病率升高相关，导致死亡率明显高于普通人群。因此，在治疗糖尿病患者时，管理心血管风险和肾脏疾病的进展似乎至关重要。新型药物类别的出现，无论血糖控制如何，都能积极影响心血管和肾脏风险，这是 T2DM 治疗领域的一场革命，将注意力从强化血糖控制转移到对糖尿病患者的全面管理。其中，钠-葡萄糖协同转运蛋白 2 抑制剂（SGLT2i）与心血管和肾脏死亡率的显著降低、心力衰竭住院率的降低以及肾脏损害和白蛋白尿的进展降低相关。因此，在选定的亚人群中使用 SGLT2i 似乎是强制性的。本综述的目的是评估 SGLT2i 的现有证据及其对心血管和肾脏特征的相关影响。
